Sugi Predict

Sugi Predict / Targets / PTPN7

PTPN7

Tyrosine-protein phosphatase non-receptor type 7 · P35236 · PTPN7 on Sugi Atlas →

96,316 patent compounds predicted against PTPN7, 74,498 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL93061 SCHEMBL93061 0.49 6/20
SCHEMBL68751 SCHEMBL68751 1.00 5/20
SCHEMBL68425 SCHEMBL68425 0.96 5/20
SCHEMBL47069 SCHEMBL47069 0.89 5/20
SCHEMBL41374 SCHEMBL41374 0.70 5/20
SCHEMBL59534 SCHEMBL59534 0.61 5/20
SCHEMBL55675 SCHEMBL55675 0.54 5/20
SCHEMBL55883 SCHEMBL55883 0.52 5/20
SCHEMBL126744 SCHEMBL126744 0.52 5/20
SCHEMBL126745 SCHEMBL126745 0.52 5/20
SCHEMBL61256 SCHEMBL61256 0.50 5/20
SCHEMBL56221 SCHEMBL56221 0.48 5/20
SCHEMBL55033 SCHEMBL55033 0.46 5/20
SCHEMBL93632 SCHEMBL93632 0.92 4/20
SCHEMBL40759 SCHEMBL40759 0.65 4/20
Exocarpic Acid Exocarpic Acid (SCHEMBL44849) 0.62 4/20
SCHEMBL93903 SCHEMBL93903 0.53 4/20
SCHEMBL93658 SCHEMBL93658 0.47 4/20
SCHEMBL8221 SCHEMBL8221 0.44 4/20
SCHEMBL15416 SCHEMBL15416 0.44 4/20

Clinical trials — most relevant to PTPN7 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Regulatory Lymphocytes in Patients Treated With Specific Immunotherapy PHASE4COMPLETED
Pegylated-Interferon and Ribavirin Plus Metformin in the Treatment of Chronic HCV Infection and Insulin Resistance PHASE4UNKNOWN
Pembrolizumab and Induction Chemotherapy in Head and Neck Squamous Cell Carcinoma (PICH Study) PHASE1/PHASE2WITHDRAWN
Pembrolizumab And Tamoxifen Among Women With Advanced Hormone Receptor Positive Breast Cancer And Esr1 Mutation PHASE2UNKNOWN
Pembrolizumab Plus Enfortumab Vedotin in Collecting Duct and Renal Medullary Carcinoma PHASE2RECRUITING
Pembrolizumab (MK-3475) in MM Patients With Residual Disease PHASE2COMPLETED
Study in Adult Ph-positive ALL PHASE2UNKNOWN
Small Cell Lung Carcinoma Trial With Nivolumab and IpiliMUmab in LImited Disease PHASE2COMPLETED
Study Evaluating Toxicity & Efficacy of Lenalidomide(Revlimid®)in Chemotherapy-Naïve AIPC Patients PHASE2COMPLETED
An Exploratory Study on the Use of Ipalotinib (Tislelizumab) Combined With Sunitinib and Olaparib for Neoadjuvant Therapy in HRD-positive Advanced Ovarian Cancer PHASE2RECRUITING
Immunoregulatory Therapy for 2019-nCoV PHASE2UNKNOWN
A Clinical Study With Tremelimumab as Monotherapy in Malignant Mesothelioma PHASE2UNKNOWN
Phase I Study of SC-43 Oral Solution in Subjects With Refractory Solid Tumors PHASE1WITHDRAWN
A Study of HMPL-415S1 in Patients With Advanced Malignant Solid Tumors PHASE1RECRUITING
Oral STAT3 Inhibitor, TTI-101, in Patients With Advanced Cancers PHASE1COMPLETED
Lymphoid Tyrosine Phosphatase Gene Polymorphisms in Inflammatory Bowel Disease nanUNKNOWN
Uncovering Genes Behind Cartilage Tumors and Vascular Anomalies Using Genomic Sequencing nanRECRUITING
Immunophenotypic Evaluation of CD305 and CD85d in B-Cell Lymphoid Neoplasms nanNOT_YET_RECRUITING
Role of NFKBIA and PTPN22 Genes Polymorphism in Acute Rejection Susceptibility After Living Donor Liver Transplantation in Egyptian Patients. nanCOMPLETED
rT3 and Inflammation in Hashimoto's Thyroiditis nanCOMPLETED
Monitoring of Breathing Effort Through Pressure Time Product Measurement Using Airway Occlusion Pressure nanUNKNOWN
Clinical Study on the Application of PET Probes Targeting DDR2 in the Diagnosis of Interstitial Lung Disease With Cognitive Impairment nanNOT_YET_RECRUITING
Resistance to Immunotherapy in Gastric Cancer nanUNKNOWN
Is T-lymphocyte Calcineurin Phosphatase Up-regulated by Treatment With Tacrolimus? nanCOMPLETED
Avapritinib in the Treatment of Unresectable or Recurrent Metastatic GIST Non-exon18 Mutations of PDGFRA nanRECRUITING
What is the Impact of TKI on Thyroid Function in CML Patients? nanNOT_YET_RECRUITING
Modulatory Effect of Prodigiosin or Pioglitazone on TIME and the Crosstalk to Immune-Checkpoint Protein(s) nanNOT_YET_RECRUITING
Pathological and Nuclear Medicine Factors for Prognosis in Lung Carcinoma nanCOMPLETED
Clinical Research for Azacitidine Combined With Low-dose Dasatinib in Maintenance Therapy of Acute Myeloid Leukemia nanUNKNOWN
Cytotoxic T Lymphocyte-Associated Antigen-4 (CTLA-4) Gene Single-nucleotide Polymorphism in Primary Immune Thrombocytopenic Purpura in Children nanNOT_YET_RECRUITING

Related proteins — ESM-2 sequence neighbours (a PTPN7 binder may also engage these)

ProteinNameSimilarity
P49445 — 1.000 P49445 →
Q8BUM3 — 0.995 Q8BUM3 →
P35234 — 0.989 P35234 →
P49446 — 0.985 P49446 →
B2GV87 — 0.984 B2GV87 →
PTPRE Receptor-type tyrosine-protein phosphatase epsilon 0.983 landscape →
PTPN5 Tyrosine-protein phosphatase non-receptor type 5 0.982 landscape →
P54830 — 0.980 P54830 →
PTPRA Receptor-type tyrosine-protein phosphatase alpha 0.980 landscape →
PTPN18 Tyrosine-protein phosphatase non-receptor type 18 0.978 landscape →
Q61152 — 0.977 Q61152 →
Q641Z2 — 0.976 Q641Z2 →
Q9ESK3 — 0.975 Q9ESK3 →
PTPRR Receptor-type tyrosine-protein phosphatase R 0.975 landscape →
PTPN6 Tyrosine-protein phosphatase non-receptor type 6 0.975 landscape →
P18052 — 0.974 P18052 →
JAK3 Tyrosine-protein kinase JAK3 0.974 landscape →
Q03348 — 0.974 Q03348 →
P29351 — 0.973 P29351 →
B4F7B7 — 0.973 B4F7B7 →
P0C599 — 0.973 P0C599 →
Q9R117 — 0.972 Q9R117 →
MATK Megakaryocyte-associated tyrosine-protein kinase 0.972 landscape →
O35239 — 0.971 O35239 →
NFKB2 Nuclear factor NF-kappa-B p100 subunit 0.971 landscape →
P0C5A0 — 0.971 P0C5A0 →
Q4RQD3 — 0.971 Q4RQD3 →
Q62132 — 0.971 Q62132 →
Q9WTK5 — 0.971 Q9WTK5 →
Q9HC96 — 0.971 Q9HC96 →